FDA expands approval of flu treatment to post-exposure prevention
The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who have been exposed to someone with flu.
鈥淭his expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,鈥 said Debra Birnkrant, M.D., director of the FDA鈥檚 Division of Antiviral Products.
Related News Articles
Headline
Five pediatric flu deaths were reported to the Centers for Disease Control and Prevention last week, pushing the total to 266 for the 2024-2025 flu season,鈥
Headline
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows鈥
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public鈥
Headline
Though seasonal flu activity is low or minimal across the country, 216 pediatric deaths associated with seasonal influenza virus infection have been tallied so鈥
Headline
The Central Nevada Health District yesterday announced the state's first case of H5N1 bird flu, a dairy farm worker who was exposed to infected cattle. The鈥
Headline
At least 24 million people have had seasonal flu this season, according to estimates from the Centers for Disease Control and Prevention. Nearly 49,000鈥